Business Context and Reporting Period
Company: Capricor Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 22, 2019
Reporting Period: Event date of July 22, 2019
Capricor Therapeutics, Inc., a Delaware corporation, reported the entry into a material definitive agreement to establish an "at-the-market" equity offering program.
Key Financial Metrics
This filing does not contain audited financial statements, revenue, profit, cash flow, or debt metrics. The only financial figure disclosed relates to the terms of the new sales agreement:
- Sales Agent Commission: 3.0% of gross proceeds per share sold.
- Stock Par Value: $0.001 per share.
Material Changes
On July 22, 2019, the Company entered into a Common Stock Sales Agreement with H.C. Wainwright & Co., LLC as the sales agent. Key terms include:
- Offering Structure: An "at-the-market" offering allowing the Company to sell shares of common stock from time to time based on instructions.
- Registration Basis: Shares will be issued pursuant to a Registration Statement on Form S-3 (originally filed October 24, 2018, amended July 17, 2019).
- Flexibility: The Company has no obligation to sell shares and may suspend or terminate the agreement at any time.
Guidance, Outlook, and Risks
Use of Proceeds: The Company intends to use net proceeds for research related to product candidates, manufacturing, working capital, and general corporate purposes. This may include acquisitions or other business combinations. The Board reserves the right to reallocate proceeds based on business developments.
Risks and Contingencies:
- The filing explicitly states it does not constitute an offer to sell or a solicitation of an offer to buy shares in jurisdictions where such offers would be unlawful.
- The number of shares eligible for sale is subject to limitations under General Instruction I.B.6 of Form S-3.
- The Company cannot specify with certainty all particular uses for the net proceeds at this time.
Investor Verification Checklist
- Verify the current number of shares outstanding to assess potential dilution from future sales under the agreement.
- Review the full text of the Common Stock Sales Agreement (Exhibit 10.1) for specific termination rights and limitations.
- Monitor subsequent filings for actual sales volumes and proceeds generated under this program.
- Confirm the status of the Form S-3 Registration Statement referenced in the filing.